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2Abstract  
Background:  
The severity of Tuberous Sclerosis Complex (TSC) can vary among affected 
individuals. Complications of TSC can be life threatening, with significant impact on 
patients’ quality of life. Management may vary dependent on treating physician, local 
and national policies, and funding. There are no current UK guidelines. We 
conducted a Delphi consensus process to reach agreed guidance for the 
management of patients with TSC in the UK.  
 
Methods:  
We performed a literature search and reviewed the 2012/13 international guideline 
for TSC management. Based on these, a Delphi questionnaire was formed. We 
invited 86 clinicians and medical researchers to complete an online survey in two 
rounds. All the people surveyed were based in the UK. Clinicians were identified 
through the regional TSC clinics, and researchers were identified through 
publications. In round one, 55 questions were asked. In round two, 18 questions 
were asked in order to obtain consensus on the outstanding points that had been 
contentious in round one. The data was analysed by a core committee and 
subcommittees, which consisted of UK experts in different aspects of TSC. The 
Tuberous Sclerosis Association was consulted.          
 
Results:  
51 TSC experts took part in this survey. Two rounds were required to achieve 
consensus. The responders were neurologists, nephrologists, psychiatrist, 
psychologists, oncologists, general paediatricians, dermatologist, urologists, 
radiologists, clinical geneticists, neurosurgeons, respiratory and neurodisability 
clinicians. 
 
Conclusions:  
These new UK guidelines for the management and surveillance of TSC patients 
provide consensus guidance for delivery of best clinical care to individuals with TSC 
in the UK. 
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3 
Introduction 
 
Tuberous Sclerosis Complex (TSC) is a genetic disease caused by mutations in the 
tumour suppressor genes TSC1 and TSC2, located on chromosomes 9 and 16.(1, 2) 
Approximately two-thirds of cases occur sporadically. The incidence has been 
estimated to be 1 per 5,800 live births.(3) The protein products of TSC1 and TSC2 
(hamartin and tuberin) function together within the cell and have an inhibitory effect 
on the mammalian target of rapamycin (mTOR), a protein kinase that influences cell 
growth and division and the synthesis of proteins and other cell components.(4) 
Mutations in either TSC1 or TSC2 lead to over-activation of the mTOR pathway and 
relatively uncontrolled cell growth that causes growth of benign tumours 
(hamartomas) in various organs, such as the brain, kidneys, skin, heart, lungs and 
bones.(5) 
 
The management of TSC has varied dependent on treating physician, local and 
national policies and funding. There are no current UK guidelines. We conducted a 
Delphi consensus process to reach agreement amongst UK experts on the 
management of patients with TSC. The Delphi process is a well established, 
commonly used and widely accepted approach to achieve consensus. It was first 
established by Dalkey et al.(6) The process has been used in other walks of life for 
example to gain consensus in programme planning, resource utilisation and policy 
making. In a Delphi process answers from expert respondents to a series of 
questions are collected in an iterative fashion until, where possible, consensus is 
achieved.   
 
The Delphi process provides consensus guidance for the delivery of best clinical 
care. It is important that the subjects are selected carefully. A danger is that when 
questions address issues without an evidence base, some respondents may provide 
answers despite a lack of specific knowledge. It is crucial, therefore, that the 
respondents are experts in the field. It is generally believed that 15-20 subjects could 
be sufficient to take part in a Delphi process but the higher the number of the 
subjects and homogeneity of response, the better the outcome. There does not 
seem to be a universally agreed proportion for Delphi consensus. It has been 
suggested that this might depend on the sample numbers, aims of the research and 
resources available. Some papers have suggested that consensus should be 
equated with 51% agreement amongst respondents; others recommend 60 or 
70%.(7) 
 
Methods: 
 
We performed a literature search and considered mortality, morbidities, diagnosis, 
treatment and surveillance of TSC. We used MEDLINE, the Cochrane library and 
google scholar to perform the search. We also reviewed the most recent 
international guidelines for TSC management.(8) Based on these, we drew up 55 
questions in round one of our Delphi survey. We created a core committee to 
oversee the questions and analyse the data. A priori consensus was defined as 70% 
agreement among participants. We invited 86 clinicians and researchers to complete 
the online survey. All the people surveyed were based in the UK. Clinicians were 
identified through the regional TSC clinics in the UK, Tuberous Sclerosis Association 
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4and British Paediatric Neurology Association  while the researchers were identified 
through publications. We invited all the first and last authors of papers on TSC 
published since January 2000 until January 2017 in the UK. Respondents were 
advised to complete only sections of the survey, which were relevant to their 
expertise. As TSC is a multi-system disease, a cardiologist, for example, may not 
want to comment on the neurological management of TSC. Conversely a 
paediatrician who provides holistic care for his/her TSC patients may have relevant 
views on several aspects of the disease. In round two, 18 questions were asked to 
obtain consensus on the outstanding points that had been contentious in round one, 
or that needed clarification. The surveys were conducted over 6 months from June 
2017-November 2017. A weekly electronic reminder was sent to the responders. The 
data were analysed by a core committee and subcommittee that consisted of UK 
experts in different fields within TSC.       
  
51 experts (60%) responded to the survey. Two rounds were required to achieve 
consensus. The responders were neurologists, nephrologists, psychiatrists, 
psychologists, oncologists, general paediatricians, dermatologists, urologists, 
radiologists, clinical geneticists, neurosurgeons, respiratory physicians and 
neurodisability clinicians. A priori consensus was defined as 70% agreement among 
participants. 
 
We are reporting the recommendations for the management of TSC based on the 
Delphi consensus results and expert opinions. For each aspect of TSC there is a 
committee to give expert opinion. Their opinion is based on their practice and latest 
evidence. The recommendations have been presented under two sections: Delphi 
consensus and expert opinion.     
 
Patient and Public Involvement 
This work has been completed with collaboration with the Tuberous Sclerosis 
Association (TSA). TSA is professional organisation providing support to families 
affected by TSC across the UK. Patients were not directly involved.   
 
 
Genetics  
 
Tuberous sclerosis complex is an autosomal dominant condition. TSC displays 
genetic heterogeneity with two known loci: TSC1 gene on chromosome 9q34.3 and 
TSC2 gene on chromosome 16p13.3.(9, 10) TSC2 mutations are more commonly 
identified in sporadic cases of TSC and more likely to be associated with severe 
disease.(11) Contiguous deletions of TSC2 and the adjacent PKD1 gene, found in a 
few per cent of patients, are associated with a high risk of severe polycystic kidney 
disease.(12) 
 
Almost three thousand different TSC-causing mutations in the TSC1 and TSC2 
genes have been identified.(13) A significant fraction (approximately 15%) of TSC 
patients have no mutation identified by conventional genetic testing. Therefore, a 
normal result does not exclude a diagnosis of TSC. 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/qjm
ed/advance-article-abstract/doi/10.1093/qjm
ed/hcy215/5104881 by St G
eorge's U
niversity of London user on 09 O
ctober 2018
5 
 
 
 
Genetics – recommendations and results of consensus  
 
Delphi consensus 
There was consensus to offer a genetic test at baseline in those with definite or 
probable TSC. Testing may clarify the diagnosis of TSC in cases that do not fulfil 
clinical criteria for a definite clinical diagnosis and is a prerequisite for the application 
of genetic technologies in family planning.(14, 15)  
 
Expert opinion  
All patients should have a three-generation family history obtained to determine if 
additional family members are affected or at risk of TSC. Genetic testing and 
counselling should be offered to individuals with TSC when they reach reproductive 
age. First-degree relatives of affected individuals should be offered clinical 
assessment and where possible genetic testing, in families in which a mutation has 
been identified in the index case. 
 
 
 
Central Nervous System 
 
Epilepsy 
  
The central nervous system is commonly involved in TSC. Epileptic seizures are a 
common presenting problem and are thought to arise from cortical / subcortical 
tubers or the surrounding tissue. Most patients with TSC present with seizures 
during infancy, typically between three and eight months old, and up to one third of 
them develop epileptic spasms. However, in some studies epileptic spasms has 
been reported to be the presenting symptoms in up to 69% of patients with TSC.(16)   
Many go on to develop refractory epilepsy throughout life.(17, 18) 
 
Epileptic spasms when combined with a hypsarrhythmic pattern on the EEG and with 
evidence of developmental arrest constitute the epilepsy syndrome known as West 
Syndrome. TSC is the cause of 10–20% of those diagnosed with West syndrome. 
Epileptic spasms can lead to severe cognitive and developmental impairment.(19) 
They are commonly misdiagnosed initially in infants, often leading to long lead-times 
between onset and initiation of effective treatment. Longer lead-times to treatment 
are associated with worse developmental outcomes.(20)  
 
Animal studies have shown that mTOR inhibitors prevent the development of 
epilepsy and underlying brain abnormalities associated with epileptogenesis in TSC 
animal models.(21) Krueger et al have recently reported that everolimus was 
associated with a clinically relevant reduction in the overall frequency of clinical and 
subclinical seizures in individuals with TSC.(22) There are other reports that 
demonstrate that mTOR inhibitors everolimus / rapamycin, are effective in the 
treatment of epilepsy associated TSC in adults and children.(23, 24) A recently 
published Phase III trial has shown that everolimus, when used as an adjunctive 
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6therapy, significantly reduced treatment-resistant focal seizures in individuals with 
TSC compared with placebo.(25)  
 
 
Epilepsy– recommendations and results of consensus  
 
Delphi consensus  
There is debate as to whether a baseline standard EEG (electroencephalogram) 
should be performed in all individuals with TSC regardless of seizure activity. There 
was no consensus on this in this survey. 68% of the responders suggested no 
baseline standard EEG when there is no suspicion of seizure activity.  
 
There was no consensus on the need for treatment of interictal epileptiform 
abnormalities on EEG in infants, children and adults with TSC without clinical seizure 
activity. There are some suggestions that treating multiple spikes on EEG before 
onset of clinical seizures may reduce the risk of later clinical seizures, modify later 
phases of epileptogenesis, and reduce the risk of both drug-resistance and 
neurodevelopmental delay associated with epilepsy.(26) However, currently this has 
not yet been corroborated with prospective randomised trials.     
 
 
 
Expert opinion 
A standard EEG in individuals with suspected seizure activity should be performed. 
Perform 24-hr video EEG if changes in sleep, behaviour, or cognitive or neurological 
function are not explained by a standard EEG. 
 
Parents should be taught to recognise epileptic spasms and focal seizures in infants, 
and EEG should be repeated urgently if there is suspicion of seizures. Paediatric 
neurologists should be involved in their care. Families and patients should be 
counselled about Sudden Unexpected Death in Epilepsy (SUDEP).(27)   
 
Vigabatrin is the recommended first-line therapy for epileptic spasms in infancy. 
Hormonal therapies (oral prednisolone or ACTH) should be used if treatment with 
vigabatrin is unsuccessful.(28) Anticonvulsant therapy of other seizure types in TSC 
should generally follow the principles used in other epilepsies. Everolimus should be 
offered, if possible, to individuals with treatment resistant focal seizures. Epilepsy 
surgery should be considered for medically refractory TSC patients, but special 
consideration should be given to children at younger ages experiencing neurological 
regression. Epilepsy surgery must be performed at designated epilepsy surgery 
centres in the UK.  
 
 
Sub-Ependymal Giant Cell Astrocytoma (SEGA)  
 
Sub-ependymal giant cell astrocytomas (SEGAs) are seen in approximately 5-20% 
of patients with TSC. They are slow growing “benign” tumours. As they often grow 
adjacent to the Foramen of Monro, they can cause hydrocephalus.(29)  
 
The management of asymptomatic SEGA lesions has been controversial because 
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removal of all lesions that have shown evidence of interval growth, whilst others 
have argued for the removal only of lesions that become symptomatic. In the 
literature, some patients had SEGA resection because they had developed 
symptomatic hydrocephalus, whereas some patients had surgery because of an 
increase in tumour size, or had early surgery to prevent complications. The outcome 
from surgery appears to be less favourable if the operation is done after the patients 
present acutely with hydrocephalus.(30, 31) 
 
It has been shown that rapamycin is effective in reducing the size of TSC related 
solid tumours such as SEGA. Franz et al treated 4 TSC patients who had SEGA with 
rapamycin at standard immunosuppressive doses (serum levels 5–15ng/ml) from 2.5 
to 20 months. It was reported that the treatment was well tolerated and all SEGAs 
showed regression. Cessation of therapy resulted in tumour regrowth in one 
patient.(22) 
 
Krueger et al investigated the efficacy and safety of everolimus in an open trial in 28 
patients with TSC who had SEGA. Everolimus was given orally, at a dose of 3.0 
mg/m2 per day, in order to attain a trough concentration of 5 to 15 ng/ml. The 
treatment was given for the median duration of 21.5 months. It was noted that 
everolimus was associated with a reduction of at least 30% of the volume of SEGA 
in 21 patients (75%) and at least 50% in 9 patients (32%). Single cases of grade 3 
treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, 
and leukopenia were reported.(22) It was also noted that the clinical and 
electrographic seizures were significantly reduced at 6 months.(32)  
 
In a phase III international, multicentre, double-blind, randomized, placebo-controlled 
trial, Franz et al evaluated the efficacy and safety of everolimus in 117 patients, aged 
between 0.8-26.6 years with SEGA.  Everolimus was associated with a significantly 
greater overall SEGA response rate (>/= 50% shrinkage), compared with placebo 
(35% vs. 0%). In addition, 78% of patients receiving everolimus showed a shrinkage 
of >/= 30% compared to 15% on placebo, and none of the patients taking everolimus 
progressed compared to 14% on placebo. This response was shown to be durable 
over 47 months.(33) The frequency of seizures was not different between the 
treatment and placebo groups. It was demonstrated that everolimus was associated 
with greater partial skin lesion (facial angiofibromas) response (42% vs. 11%). In 
addition, angiomyolipoma (AML) response rates were 53% vs. 0%, compared with 
the placebo group.(32) 
 
SEGA- recommendations and results of consensus  
 
Delphi consensus  
There was consensus that patients with newly diagnosed or suspected TSC, should 
have magnetic resonance imaging (MRI) of the brain to assess for the presence of 
SEGA.  
 
There was consensus to perform MRI of the brain every 1-3 years in asymptomatic 
TSC patients without SEGA younger than 25 years of age, to monitor for growth or 
new occurrence. It is believed that the majority of these lesions stop growing in third 
decade of life.(29) However, there are some case reports of SEGA growth after the 
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8age of 25.(29) There was consensus to stop performing routine brain MRI scan at 
the age of 25 if there is no evidence of SEGA lesions.   
 
There was consensus that MRI scan should be repeated in asymptomatic patients 
with SEGA. 56% of the responders suggested that the scan should be repeated 1-3 
yearly. There was no consensus as to when to stop routine brain MRI scans in 
individuals with SEGA lesions. However, most responders suggested that this should 
be judged case by case, depending on their learning disabilities, communication 
abilities, and the SEGA interval growth.      
 
There was consensus that symptomatic and asymptomatic SEGA lesions, which are 
actively growing and likely to enlarge beyond 1cm, should be treated.  
 
There was consensus that the first line treatment for growing SEGA lesions should 
be surgery. There was consensus that growing SEGA lesions should be discussed 
at an MDT meeting that should include neurosurgeons, neurologists (paediatric or 
adult as appropriate), neuroradiologists and clinicians expert in the management of 
TSC (if not already covered by clinicians already listed).  
 
Expert opinion 
Patients with large or growing SEGA, or with SEGA causing ventricular enlargement 
who remain asymptomatic, should undergo MRI scans more frequently, and the 
patients and their families should be educated regarding the potential for new 
symptoms. 
 
Surgical resection should be performed in a specialised centre with expertise in 
resecting intraventricular lesions.(29) In determining the best treatment option, 
discussion of the complication risks, adverse effects, costs, length of treatment, and 
potential impact on TSC-associated comorbidities should be included in the decision-
making process. Patients, carers and parents should be part of this decision making 
process. 
 
The NHS England commissioning policy states that the inclusion criteria for treatment 
with everolimus are as follows: 
 
“Patient presents with SEGA lesion(s) and has at least one lesion of baseline longest 
diameter 1cm as assessed by multiphase MRI and is considered not amenable to 
surgery as assessed by a properly constituted MDT (as defined in the Governance 
Arrangements).  
  
Specifically, MDT decides that: 
 
• SEGA is too difficult to remove surgically; OR 
• SEGA needs reduction in size prior to surgery; OR 
• SEGA lesion(s) are multiple or infiltrative; OR 
• Surgery has been performed and there is residual SEGA (i.e. it was not 
possible to completely excise) that needs treating. 
 
AND  
The patient presents with: 
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MDT since patient’s last annual MRI); OR 
• unequivocal worsening of non-target lesions of SEGA; OR 
• the appearance of new lesion(s) of baseline longest diameter 1cm; OR 
• symptoms of new or worsening hydrocephalus (but where urgent surgery is 
not required); OR 
• patient presents for the first time with lesion(s) of baseline longest diameter 
1cm (accounting for patients not cared for in a surveillance programme); OR 
• partially excised SEGA lesion(s) known to be growing before surgery.  
 
Exclusion criteria:  
Any patient presenting with raised intracranial pressure (a surgical solution would be 
necessary as it would not be possible to wait for mTOR inhibition to take effect).”  
 
 
 
Neurodevelopmental and Neuropsychiatric disorders  
 
Approximately 25-60% of individuals with TSC have autistic spectrum disorders 
(ASD).(34) There are multiple factors contributing to the development of ASD in TSC 
including epilepsy during the critical period of brain development (35) and the 
existence of tubers in the temporal lobe.(36) Approximately 30–60% of patients with 
TSC have symptoms related to attention-deficit–hyperactivity disorder (ADHD).(37) 
The exact cause of attentional problems is not known but it is believed to be 
multifactorial. There is an elevated prevalence of 
neuropsychiatric/neurodevelopmental disorders in TSC such as depression, bipolar 
disorder, anxiety, schizophrenia, psychosis, auditory hallucinations and anorexia 
nervosa.(38, 39)   
 
 
Neurodevelopmental and Neuropsychiatric disorders  
Recommendations and results of consensus  
Delphi Consensus  
There was consensus that a baseline assessment for 
neuropsychiatric/neurodevelopmental conditions including autism spectrum disorder 
and attention deficit hyperactivity disorder, or marked behavioural disturbances 
should be performed.   
 
There was consensus to use the TSC Associated Neuropsychiatric Disorders 
(TAND) check list annually to check if there is any evidence of 
neuropsychiatric/neurodevelopmental disorders. In depth assessment should be 
undertaken when indicated. Treatment should follow the NICE guidelines.  
There was consensus that developmental status should be formally evaluated at key 
developmental time points and periods of transition, which are infancy (0-3 years), 
preschool (3-6 years), middle school (6-11 years), adolescence (12-18 years), and 
as clinically indicated. This is to identify specific educational/cognitive disorders and 
intellectual disabilities. It informs treatment and care planning and choice of 
educational provision. Consideration should be given to the need for support for 
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special educational needs and an assessment for an Education and Health Care 
Plan (EHCP). 
 
Expert opinion 
Marked changes in behaviour/cognitive status (either sudden or insidious), should 
prompt investigation for possible medical complications of TSC (e.g. SEGA; 
seizures; non-convulsive status; metabolic disturbances; adverse side effects of 
medications, etc.). 
 
TSC clinics should have established links and care pathways with developmental 
paediatric, educational and CAMHS specialist services to help ensure an integrated, 
responsive and timely multidisciplinary approach, which includes consultation and 
liaison.   
 
 
Kidney  
 
Angiomyolipoma (AML)  
 
Renal involvement is potentially serious and common in TSC. AMLs and cysts are 
the two characteristic renal lesions.(40) AML was first described by Grawitz in 1900 
who used the term ‘renal angiomyolipoma’ to describe a large renal tumour 
comprised of fat, muscle, and blood vessels.(41) 
 
Renal AMLs can be associated with TSC, and with sporadic 
lymphangioleiomyomatosis (LAM) in individuals that do not have systemic features 
of TSC. Growth of AMLs in individuals with TSC is often first detected during 
childhood and they tend to increase in number and size with age.(42) Approximately 
80% of patients with TSC have AMLs and 30% have cysts.(40) AML is the leading 
cause of death in individuals with TSC.(27) The presenting features of AMLs are 
haematuria, pain, high blood pressure and premature loss of glomerular filtration rate 
(GFR). Haematuria can sometimes be life threatening. (27, 43) AMLs frequently 
develop aneurysms that can rupture and can cause retroperitoneal haemorrhage or 
haematuria. Up to 20% of patients with such haemorrhage present in hypovolemic 
shock.(44) Patients with AMLs are likely to require lifelong health-care follow-up.  
 
Bissler et al. investigated rapamycin in TSC patients and patients with sporadic LAM 
with renal AMLs. This study was a non-randomized, open-label trial to study whether 
rapamycin reduces the AML size in these patients. Rapamycin was given for 12 
months. 18 patients completed a 24-month assessment.  Kidney AML volumes were 
reduced to approximately 53% of the baseline value after 12 months of starting the 
drug. Tumour regrowth to 86% of the baseline value was noted at 24 months. Five 
patients had six serious adverse events while receiving rapamycin, including 
diarrhoea, pyelonephritis, stomatitis, and respiratory infections.(45) 
 
In a multicentre, phase 2 trial, Davies et al investigated the efficacy and safety of 
rapamycin for AML in adults with TSC, or sporadic LAM. 16 patients, who had AMLs 
of more than 2 cm diameter, were treated with rapamycin for up to 2 years.  Patients 
received daily oral doses of rapamycin to achieve initial trough blood levels of 3 to 6 
ng/ml, with an increase to 6 to 10 ng/ml at 2 months. They reported shrinkage of 
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AMLs in all patients, and that 8 (50%) had a formal partial response by RECIST* 
criteria (*Response Evaluation Criteria In Solid Tumours) of a 30% or more reduction 
in the sum of the longest diameters of their AMLs. They reported that all patients 
suffered from grade 1 or 2 adverse events such as mouth ulcers, hyperlipidemia, and 
peripheral oedema. The treatment had to be terminated in one patient due to side 
effects. In addition, the tumour size increased upon treatment cessation.(46, 47)  
 
Similar results were obtained in another placebo-controlled trial of sirolimus by 
Dabora and colleagues.(48) 
 
Exist-2 was a placebo controlled phase 3 RCT investigating the efficacy and safety 
of everolimus in treating renal AMLs > 3cm in adults. 118 patients (median age 310 
years; IQR 180–610) were randomly assigned to receive everolimus (n=79) or 
placebo (n=39). At the data cut-off in the first report,(49) double-blind treatment was 
on-going for 98 patients; the two main reasons for discontinuation were disease 
progression (nine placebo patients) followed by adverse events (two everolimus 
patients; four placebo patients). The AML response rate (Defined as >/= 50% 
shrinkage) was 42% (33 of 79 [95% CI 31–53%]) for everolimus and 0% (0 of 39 [0–
9%]) for placebo one-sided Cochran-Mantel-Haenszel test p<00001). The most 
common adverse events in the everolimus and placebo groups were stomatitis (48% 
[38 of 79], 8% [3 of 39], respectively), nasopharyngitis (24% [19 of 79] and 31% [12 
of 39]), and acne-like skin lesions (22% [17 of 79] and 5% [2 of 39]). In addition, 80% 
of everolimus patients had a >/= 30% reduction in AML volume compared to 3% on 
placebo. By 12 months 8% of the everolimus patients and 75% 
of the placebo patients had shown progression – but none of the everolimus patients 
who showed a response progressed. This response was durable up to 46.9 
months.(50)  
 
 
AML – recommendations and results of consensus 
 
Delphi consensus 
Consensus was reached on the management of kidney AMLs. For newly diagnosed 
or suspected patients with TSC, an MRI of the abdomen should be performed to 
assess for the presence of AML and renal cysts, regardless of age. MRI is the 
optimal imaging modality as some lesions, such as fat poor AMLs, can be over 
looked on ultrasound scans. CT is an alternative to MRI but the cumulative dose of 
ionising radiation needs to be considered. Both the brain and kidney MRI scans 
should ideally be combined and be done at the same time. MRI of the abdomen may 
also reveal aortic aneurysms or extrarenal hamartomas of the liver, pancreas, and 
other abdominal organs that can also occur in individuals with TSC.(27)  
 
Patients should be screened for secondary hypertension by measuring blood 
pressure. At the time of diagnosis renal function (i.e. glomerular filtration rate) should 
be evaluated.(51, 52) 
 
There was consensus that all patients with TSC should have regular kidney imaging. 
68% of the responders suggested that kidney imaging should be repeated annually 
and 28% suggested that the kidney imaging should be repeated every 2 years.  
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There was consensus that blood pressure measurement and kidney function tests 
should be repeated annually.  
 
There was consensus that growing AMLs measuring ≥3cm in diameter should be 
treated with mTOR inhibitors.  
 
Expert opinion 
For existing patients, if general anaesthetic (GA) is not required, they should have 
annual MRI of the abdomen to assess for the progression of AML and renal cystic 
disease throughout their lifetime. If GA is required, and on MRI the anatomy and 
pathology are judged to be easy to interpret by ultrasound scan, then the next 
surveillance scan or two could be ultrasound. Patients with Vagal Nerve Stimulator 
may not be able to have MRI scan. CT scan can be performed for those patients. 
 
Everolimus is licensed for the treatment of growing AMLs that are > 3cm and not 
acutely bleeding in adults. It is funded for use in the NHS for adults and children (for 
whom it is off license) because the results from Exist-1 show it is highly effective in 
children.(53, 54) Selective embolization or kidney-sparing resection are possible 
second-line therapies for asymptomatic AMLs. 
 
Embolization followed by corticosteroids is first-line therapy for AML presenting with 
acute haemorrhage. Nephrectomy should be avoided, if possible. 
 
 
Lung 
 
Lymphangioleiomyomatosis (LAM) 
 
Pulmonary LAM occurs almost exclusively in female patients. However, there are 
some case reports of male individuals with LAM and TSC. The true prevalence of 
LAM lesions is not well known as not all TSC patients are screened for LAM. They 
can present with progressive shortness of breath, recurrent pneumothoraces, and 
deterioration in lung function.(55)  
 
LAM is characterized by abnormal proliferation or infiltration of smooth muscle cells, 
lymphatic vessels and cystic destruction of the lung. These cells are thought to 
express a melanogenisis-associated antigen recognized by HMB45 and they may 
express estrogen and progesterone receptor proteins.(56) 
 
Mutations in TSC2 gene occur in both TSC-associated and sporadic LAM smooth 
muscle cells and lead to overactivation of the mTOR pathway. mTOR inhibitors, such 
as rapamycin, have been shown to improve lung function in patients with LAM and 
reduce the size of the lesions. However, it has been found that lung function declines 
and the lesions re-grow once the drug is discontinued.(57) 
 
 
 
 
LAM – recommendations and results of consensus  
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Delphi consensus  
There was consensus in this Delphi process to perform a baseline high-resolution 
chest computed tomography (HRCT) in females of child-bearing age. There was 
consensus to repeat HRCT in patients with LAM. The frequency of the scans should 
depend on patient’s disease progression. There was consensus that individuals with 
LAM detected on HRCT should have annual pulmonary function testing and 6-
minute walk test where practicable, and these should be repeated more frequently in 
those have progressive disease.   
 
There was consensus to offer HRCT every 5-10 years to women without LAM on 
their baseline scan, or if symptoms of LAM develop. This should be performed until 
the menopause. There was no consensus on performing routine baseline pulmonary 
function testing or 6-minute walk test in patients who are newly diagnosed, or have 
suspected TSC. 
 
There was consensus that mTOR inhibitors should be used to treat individuals with 
LAM if there is evidence of progressive LAM lesions.   
 
 
Expert opinion 
Assessment of those with LAM who are unable to perform pulmonary function 
testing, including those with learning difficulties, may be more difficult. Carers should 
be aware of the significance of increasing dyspnoea and the symptoms of 
pneumothorax. Clinical assessment should include a discussion of LAM symptoms, 
including exertional dyspnoea and pneumothorax with the individual and their carers. 
Six-minute walk testing or informal assessment of hypoxaemia during exertion may 
still be possible and may identify progressive lung disease. HRCT can be performed 
as described above and if there are otherwise unexplained worsening of respiratory 
symptoms. 
 
Adult males should also undergo testing if they are symptomatic. Adolescent and 
adult females should be offered counselling on oestrogen use. All patients should be 
offered counselling regarding smoking risk. There is some evidence that oestrogen-
containing contraceptives can exacerbate pulmonary LAM.(58, 59) 
 
mTOR inhibitors should be used to treat individuals with LAM if there is evidence of 
progressive LAM lesions or loss of lung function ie if lung function falls more quickly 
than expected for age.(60) Patients with progressive disease or specific 
complications for which no other therapy is available should be considered for 
treatment with an mTOR inhibitor. Those likely to benefit from an mTOR inhibitor 
according to current evidence are those with progressive deterioration in lung 
function and those with chylous complications.   
 
 
 
 
 
 
Skin 
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Skin involvement is common in TSC. Lesions such as facial angiofibromatosis, 
hypomelanotic macules, shagreen patches, forehead fibrous plaques, skin tags and 
periungual fibromas are observed in individuals with TSC.(3)  
 
Facial angiofibromas can affect approximately 86% of patients with TSC.  They are 
benign tumours on the face that generally become noticeable at around the age of 
five years. They can have a huge impact on a patient’s self-esteem. In addition, they 
are known to cause recurrent bleeding, irritation, infection, facial scarring and 
disfigurement.(61)  
 
Systemic mTOR inhibitors such as everolimus and rapamycin have been used to 
treat TSC related complications and it has been shown that they improve facial 
angiofibromas.(22, 32) However, their use is constrained by concerns about 
systemic side effects. There have been several case reports of the use of topical 
sirolimus ointment for the treatment of facial angiofibromas. Different sirolimus 
ointment strength, preparation and regimes have been used. Amin et al used 
sirolimus ointment 0.1% for facial angiofibromas in children and adults with TSC, 
using a standardised and validated facial angiofibroma severity index to measure 
outcome. They also assessed the effect of this treatment on quality of life. It was 
noted that objective assessment shows that sirolimus ointment 0.1% administered 
once a day in a clinic setting is effective in treating facial angiofibromas. It is safe and 
well tolerated. It has a positive impact on patients’ quality of life and it is likely to be 
most beneficial when started in childhood.(48, 62-65)  
   
Skin – recommendations and results of consensus  
 
Delphi consensus  
There was consensus to perform a detailed clinical dermatological inspection/exam 
using Wood’s light in newly diagnosed or patients with suspected TSC. Then, an 
annual clinical dermatological inspection/examination should be performed. There 
was consensus that facial angiofibromas can be treated with topical mTOR 
inhibitors.  
 
Expert opinion 
Currently, funding is not available for topical mTOR inhibitors for all patients in the 
UK. Some patients are obtaining this treatment via Individual Funding Request (IFR) 
through TSC clinics.  
 
Laser treatment can also be used for treating facial angiofibromas.(63, 66) Surgical 
excision can be considered for larger solitary lesions. Surgical excision can be 
considered for ungual fibromas which are causing problems. 
 
Teeth  
 
Dental enamel pitting is observed in most patients with TSC. Dental pitting can also 
be observed in the general population, but at lower frequency and with fewer lesions 
than in TSC. Oral fibromas are also common in adults with TSC. They are mostly 
gingival but they can occur on the tongue.(67) 
 
Teeth – recommendations and results of consensus  
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Expert opinion 
Periodic oral evaluation should occur every 6-12 months, consistent with surveillance 
recommendations for all individuals in the general population. Periodic preventive 
measures as well as oral hygiene education, especially in patients with learning 
disabilities, is important. 
 
Dental pits can be treated with restorative treatments if the patient is at high cavity 
risk, although they rarely cause symptoms or an increased incidence of dental 
decay.(68) 
 
Oral fibromas can be excised surgically if symptomatic or if interfering with oral 
hygiene. Oral fibromas may recur once excised; therefore, periodic oral evaluation is 
encouraged.(69) 
 
 
Heart  
 
Cardiac rhabdomyomas are the most common heart tumours in children and are 
closely associated with TSC. The prevalence of TSC associated with fetal cardiac 
rhabdomyoma is at least 50–80%. The presence of multiple rhabdomyomas 
correlates very highly with a diagnosis of TSC, and is likely to approach 100%.(70) 
Most cardiac rhabdomyomas either partially or completely regress during the first 2–
4 years.(71) However, they can cause life-threatening complications such as intra-
cavity obstruction, diminished myocardial function, and rhythm disturbances.(72) 
 
 
Heart – recommendations and consensus  
 
Delphi consensus 
There was consensus that a baseline electrocardiogram (ECG) should be performed 
in all patients to check for arrhythmia and conduction abnormalities such as Wolff–
Parkinson–White syndrome (WPW).(73) There was consensus that all children and 
symptomatic adults at baseline should be offered an echocardiogram to evaluate for 
rhabdomyomas.  
 
There was consensus to repeat echocardiogram in asymptomatic patients with 
rhabdomyomas. 53% of the responders suggested that an echocardiogram should 
be repeated every 1-3 years in asymptomatic patients, until either there is complete 
regression of cardiac rhabdomyomas or the first signs of regression.  
 
In addition, there was consensus to perform a 12- lead ECG at a minimum of every 
3-5 years. 
 
Expert opinion 
The natural history of these lesions is spontaneous regression. It may not be 
necessary to continue scanning these patients until complete regression. Continuous 
scanning is not beneficial in the absence of cardiac symptoms.   
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In patients with clinical symptoms, additional risk factors, or significant abnormalities 
on routine echocardiogram or ECG, more frequent interval assessment may be 
needed and may include ambulatory event monitoring. Patients with hemodynamic 
instability and or life threatening arrhythmia should be treated with antiarrhythmic 
medications, surgery or mTOR inhibitors depending on the situation.(74)  
 
 
Eye  
 
Approximately half of patients with TSC have retinal or optic nerve hamartomas; in 
half of these patients the hamartomas occur bilaterally.  
 
Three morphological types of retinal hamartomas have been reported in 
literature:(75-77) 
 
1. flat, smooth, non-calcified, grey, translucent lesions; 
2. elevated, multinodular, calcified, opaque lesions, resembling mulberries; 
3. transitional lesions which have morphological features of both the first and 
second types.  
 
Other retinal findings which have been reported include retinal pigmentary 
disturbances, ranging from hyperpigmented areas to hypopigmented areas at the 
posterior pole or midperiphery.(78) Non-retinal findings in TSC include angiofibromas 
of the eyelids, coloboma of the iris, lens and choroid, strabismus, poliosis of 
eyelashes, papilloedema, and sector iris depigmentation.(79) 
 
Eye – recommendations and results of consensus  
 
Delphi consensus  
There was consensus to perform a baseline ophthalmologic evaluation, including 
fundoscopic evaluation for all individuals diagnosed with TSC to evaluate for 
hamartomas and hypo-pigmented lesions of the retina.  
 
There was no agreement on whether routine ophthalmic assessment should just be 
fundoscopy by direct ophthalmoscopy or a detailed ophthalmological review by an 
ophthalmologist.  
 
Expert opinion 
It may be unachievable to aim to offer a detailed ophthalmology review regularly. It is 
very rare for retinal hamartomas to cause problems. It is necessary that these 
patients receive a regular fundoscopy examination during their clinic visits to check 
for papilloedema. Symptomatic changes due to retinal hamartomas are very rare. 
Macular oedema and vitreous haemorrhage have been thought to associated with 
retinal hamartomas. More frequent assessment, including in those treated with 
vigabatrin, is of no proven benefit and not recommended unless new clinical 
concerns arise.(80)  
 
Table 1 and 2 show surveillance and management recommendations for newly 
diagnosed or suspected TSC, and for patients already diagnosed with TSC.    
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Conclusion  
 
An agreed guideline for managing patients with TSC should improve the complex 
and multi-specialty issues faced by patients with this rare disorder. The clinical 
presentation of TSC is variable and the progression and severity of organ 
involvement can vary according to the individual’s age, genotype and treatment. 
Consequently it is challenging to manage TSC patients optimally without the 
guidance of an evidence based approach agreed by a range of specialists with 
appropriate expertise. Most patients in the UK should have access to regional TSC 
specialist clinics where multisystem management can be coordinated. However, 
there is a wide variation in the type and the quality of care they receive, due to 
limited awareness and variable funding. The aim of this consensus guideline is to 
agree surveillance and management expectations for TSC patients in UK. In 
addition, this information should be available to those professionals who are 
managing TSC patients locally. It will also help policy makers and planners to plan 
and allocate budgets for TSC services. The financial and technological limitations of 
the NHS in the UK currently prevent implementation of some of the 2013 
International Consensus Guidelines for TSC surveillance and management. In 
addition, they do not reflect the UK opinion. The guidance suggested here was 
determined by conducting a Delphi process undertaken by TSC experts working in 
the NHS across the UK and attempts to set out a realistic standard that should be 
achievable in this setting. 
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Table 1: Surveillance and management recommendations for newly diagnosed 
or suspected tuberous sclerosis complex (TSC)  
Genetic screening at baseline 
Genetic testing should be offered at baseline to all patients consensus 
If it is impossible to offer genetic testing to all patients, then genetic 
testing should be offered for reproductive counselling or when a TSC 
diagnosis is likely but cannot be clinically confirmed 
expert opinion 
Obtain three-generation family history expert opinion 
First-degree relatives of individuals with TSC should be offered clinical 
assessment and where possible genetic testing 
expert opinion 
Ensure that the availability of preimplantation, prenatal and non-
invasive prenatal diagnosis options is discussed where appropriate 
expert opinion 
 
Central nervous system screening at baseline 
Perform MRI of the brain for all patients consensus 
Perform a baseline assessment for neuropsychiatric / 
neurodevelopmental disorders 
consensus 
Obtain a standard EEG in individuals with suspected epileptic seizure 
activity 
consensus 
Perform 24-hr video EEG, if changes in sleep, behaviour, or cognitive or 
neurological function are not explained by a standard EEG 
expert opinion 
Teach parents to recognise infantile spasms and focal seizures and 
repeat EEG urgently if there is a suspicion of seizures. Paediatric 
neurologists should be involved in their management 
expert opinion 
 
Kidney screening at baseline  
Perform MRI of the abdomen. consensus 
If MRI is contraindicated, perform CT or ultrasound scan expert opinion 
Check blood pressure and glomerular filtration rate (GFR) consensus 
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Lung screening at baseline  
Perform baseline high-resolution chest computed tomography (HRCT) 
in females of child-bearing age 
consensus 
Adult males, if symptomatic, should also undergo HRCT expert opinion 
Provide counselling on oestrogen use in adolescent and adult females expert opinion 
Provide counselling on smoking risks in all patients expert opinion 
 
 
Skin screening at baseline  
Perform a detailed clinical dermatological inspection/exam using 
Wood’s light 
consensus 
 
Dental screening at baseline  
Perform a detailed clinical dental inspection/exam looking for abnormal 
tooth eruption, dental pits and oral fibromas 
expert opinion 
 
 
Heart screening at baseline  
Perform a baseline ECG consensus  
Perform a baseline echocardiogram in all children and symptomatic 
adults. 
consensus 
 
Eye screening at baseline  
Perform a complete ophthalmologic evaluation, including dilated 
fundoscopy, to assess for retinal lesions and visual field deficits. 
consensus 
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Table 2: Surveillance and management recommendations for patients already 
diagnosed with definite or possible tuberous sclerosis complex (TSC)  
 
Genetic surveillance  
First-degree relatives of individuals with TSC should be offered clinical 
assessment and where possible genetic testing. 
expert opinion 
Ensure that the availability of preimplantation, prenatal and non-
invasive prenatal diagnosis options is discussed where appropriate. 
expert opinion 
 
SEGA surveillance  
Perform MRI of the brain every 1-3 years in asymptomatic TSC 
patients, without SEGA, younger than age 25. 
consensus 
Perform MRI of the brain every 1-3 years in asymptomatic TSC 
patients, with SEGA 
consensus 
There was no consensus as to when to stop routine brain MRI scans in 
individuals with SEGA lesions. However, most responders suggested 
that this should be judged case by case, depending on their learning 
disabilities, communication abilities, and the SEGA interval growth. 
consensus  
Patients with large or growing SEGA, or with SEGA causing ventricular 
enlargement who remain asymptomatic, should undergo MRI scans 
more frequently, and the patients and their families should be 
educated regarding the potential of new symptoms 
expert opinion 
Growing SEGAs should be discussed at MDT with oncologists, 
neurologists, neuro-radiologists, neurosurgeons and TSC experts 
consensus 
The patient or family should be involved in this discussion. expert opinion 
The first line of treatment for growing SEGAs is surgery consensus 
Surgical resection should only be performed in a specialised centre 
with expertise in resecting intraventricular lesions if possible 
expert opinion 
Everolimus can be offered as per NHS England commissioning criteria expert opinion 
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Surveillance for neurodevelopmental and Neuropsychiatric disorders  
At each annual clinical review, the TAND check list should be used consensus 
In-depth neuropsychology and neuropsychiatric assessments should 
be undertaken when indicated 
consensus 
Treatment should follow the NICE guidelines expert opinion 
Developmental status should be formally evaluated at key 
developmental time points and periods of transition, which are infancy 
(0-3 years), preschool (3-6 years), middle school (6-11 years), 
adolescence (12-18 years), and as clinically indicated 
consensus 
TSC clinics should have established links and care pathways with 
developmental paediatric, educational and CAMHS specialist services 
to help ensure a seamless, integrated, responsive and timely 
multidisciplinary approach, which includes consultation and liaison 
expert opinion 
 
Epilepsy surveillance  
Obtain a standard EEG in individuals with suspected epileptic seizure 
activity 
consensus 
Perform 24-hour video EEG, if changes in sleep, behaviour, or 
cognitive or neurological function are not explained by a standard EEG 
expert opinion 
Vigabatrin is the recommended first-line therapy for infantile spasms. 
Hormonal treatments should be used if treatment with vigabatrin is 
unsuccessful 
expert opinion  
Everolimus should be offered, if possible, to individuals with treatment 
resistant focal seizures 
expert opinion 
Epilepsy surgery should be considered for TSC patients with refractory 
epilepsy.  
expert opinion 
Families and patients should be counselled about the risk of SUDEP expert opinion 
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Kidney surveillance  
Kidney imaging should be repeated regularly  consensus  
If a GA is not required, patients with renal lesions, should have annual 
MRI of the abdomen to assess for the progression of AML, renal cystic 
disease and occurrence of the rare renal cancer throughout the lifetime 
of the patient. If MRI scan is impossible to perform annually and if on 
MRI the anatomy and pathology are judged to be easy to interpret by 
ultrasound scan, then the next surveillance scan or two could be an 
US, or fast low dose CT scan could be used 
expert opinion 
In the absence of renal lesions, the scans should be repeated every 1-
3 years through childhood and early adult life 
expert opinion 
If GA is required and on MRI the anatomy and pathology are judged to 
be easy to interpret by US scan, then the next surveillance scan or two 
could be an US, or the new fast low dose CT scan could be used if this 
avoids an anaesthetic 
expert opinion  
Assess renal function (including determination of glomerular filtration 
rate [GFR]) and blood pressure annually in adults and children with 
renal lesions 
consensus 
Embolization covered by corticosteroids is first-line therapy for AMLs 
presenting with acute haemorrhage 
expert opinion 
Every attempt should be made to avoid nephrectomy expert opinion 
For asymptomatic, growing AML measuring larger than 3 cm in 
diameter, treatment with an mTOR inhibitor is the recommended first-
line therapy 
consensus 
Selective embolization or kidney-sparing resections are possible 
second-line therapies for asymptomatic AMLs 
expert opinion 
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Lung surveillance  
Provide counselling on oestrogen use in adolescent and adult females expert opinion 
Provide counselling on smoking risks in all patients expert opinion 
Obtain HRCT every 5-10 years in asymptomatic females of 
childbearing age, if there is no evidence of LAM on their baseline 
HRCT. This should be performed until menopause 
consensus 
Individuals with LAM detected on HRCT should have annual 
pulmonary function testing (pulmonary function testing and 6-minute 
walk test) and more often if they have progressive disease 
consensus 
mTOR inhibitors should be used to treat individuals with LAM if there is 
evidence of progressive loss of lung function 
consensus 
 
Skin surveillance  
Perform a detailed clinical dermatologic inspection/exam annually consensus 
Patients and families should be counselled to use sunblock (SPF 30+) 
routinely 
expert opinion 
Facial angiofibromas should be treated with topical mTOR inhibitors consensus 
Laser treatment can be used to treat these lesions expert opinion  
Surgical excision can be considered for larger solitary lesions expert opinion 
Surgical excision can be considered for ungual fibromas that are 
causing problems 
expert opinion 
 
Teeth surveillance  
Periodic oral evaluation should occur every 6-12 months, consistent 
with surveillance recommendations for all individuals in the general 
population. Periodic preventive measures as well as oral hygiene 
education especially in patients with learning disabilities are important 
expert opinion 
Symptomatic or deforming dental lesions, oral fibromas, and bony jaw 
lesions can be treated with surgical excision or curettage when present 
expert opinion 
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Heart surveillance  
Echocardiogram should be repeated every 1-3 years in asymptomatic 
patients until either complete regression of cardiac rhabdomyomas or 
until first sign of cardiac rhabdomyomas regression 
consensus 
12- lead ECG is recommended at minimum every 3-5 years consensus 
In patients with clinical symptoms, additional risk factors, or significant 
abnormalities on routine echocardiogram or ECG, more frequent 
interval assessment may be needed and may include ambulatory 
event monitoring 
expert opinion 
Patients with hemodynamic instability and or life threatening 
arrhythmia should be treated 
expert opinion  
 
Eye surveillance  
Regular fundoscopy by direct ophthalmoscopy examination during 
each clinic visit should be performed  
consensus 
More frequent assessment, including those treated with vigabatrin, is 
of no proven benefit and not recommended unless new clinical 
concerns arise 
expert opinion 
 
Liver and pancreatic surveillance  
Liver and pancreas should be assessed for lesions during annual 
abdominal MRI scan 
consensus 
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